Objectives: This study aimed to determine molecular characteristics of , and genes in isolated from a cohort of Indonesian patients with tuberculosis.

Methods: Fifty isolates of were analysed by testing (DST) for susceptibility to first- and second-line drugs using the proportional method in a liquid medium. The genomic material was extracted to perform multiplex polymerase chain reaction (PCR) for identification and gene sequencing of , and .

Results: Approximately 80% (40/50) of the mutations that were detected outside the hot-spot region (S450L, H445D, D435V, S441L, I491F, and Q432P) conferred rifampicin-resistance on . Approximately 11.42% (4/35) of isolates with S315T mutation in led to rifampicin-resistance instead of isoniazid-resistance. The mutation in gene was found at various locations (P280P, G279R, E340Q, T271I, E340*stop codon, R373G, and S315N). Streptomycin-resistance was detected in 42% (21/50) of the strains, but only two strains had gene mutations (G878A and/or S514R). Approximately 14% (7/50) of isolates were kanamycin- and capreomycin-resistant but did not harbour mutations in the gene, while 80% (40/50) of the strains had mutations in the quinolone-resistance determining region (QRDR) of the gene (S95T, D94V, A90V, and S91P) including the pan-susceptible strain.

Conclusions: Of the 50 strains analysed, most of the mutations in the gene associated with rifampicin-resistance were also detected in the and genes. Molecular characterisation using DNA sequencing techniques is a highly sensitive approach for detecting mutations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033412PMC
http://dx.doi.org/10.1016/j.jtumed.2019.12.003DOI Listing

Publication Analysis

Top Keywords

molecular characterisation
8
first- second-line
8
second-line drugs
8
indonesian patients
8
80% 40/50
8
mutations gene
8
mutations
7
gene
6
characterisation mutations
4
mutations associated
4

Similar Publications

Background: Small, soluble oligomers, rather than mature fibrils, are the major neurotoxic agents in Alzheimer's disease (AD). In the last few years, Aprile and co-workers designed and purified a single-domain antibody (sdAb), called DesAb-O, with high specificity for Aβ oligomeric conformers. Recently, Cascella and co-workers showed that DesAb-O can selectively detect synthetic Aβ oligomers both in vitro and in cultured cells, neutralizing their associated neuronal dysfunction.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Shoolini University, Solan, Himachal Pradesh, India.

Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline, neuroinflammation, and mitochondrial dysfunction. In Alzheimer's, abnormal Mitochondrial Permeability Transition Pore (mPTP) activity may contribute to mitochondrial dysfunction and neuronal damage. Withanolide A, a naturally occurring compound derived from Withania somnifera, have shown potential neuroprotective effects in various neurological disorders.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Background: Our limited understanding of the mechanisms that trigger the emergence of Alzheimer's disease (AD) has contributed to the lack of interventions that stop, prevent, or fully treat this disease. We believe that developing a nonhuman primate model of AD will be an essential step toward overcoming the limitations of other model systems and is crucial for investigating primate-specific mechanisms underlying the cellular and molecular root causes of the pathogenesis and progression of AD.

Method: The consortium successfully generated viable founders carrying PSEN1 mutations.

View Article and Find Full Text PDF

Background: The goal of the TREAT-AD Center is to enable drug discovery by developing assays and providing tool compounds for novel and emerging targets. The role of microglia in neuroinflammation has been implicated in the pathogenesis of Alzheimer's disease (AD). Genome-wide association studies, whole genome sequencing, and gene-expression network analyses comparing normal to AD brain have identified risk and protective variants in genes essential to microglial function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!